由美国临床肿瘤学会（ASCO）、美国胃肠病学协会（AGA）、美国放射肿瘤学会（ASTRO）和美国肿瘤外科学会（SSO）共同主办的第20届美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI 2023）将于当地时间2023年1月19日至21日以线上结合线下的形式举行，线下地点为美国旧金山Moscone West会展中心。
作为全球唯一且最为盛大的消化肿瘤年度学术会议，此次ASCO GI迎来了其20周年纪念日。
日前，ASCO官网发布了ASCO GI 2023的全体大会、口头报告及快速口头报告专场的摘要题目，【肿瘤资讯】特此整理，以飨读者。
全体会议（General session）
Abstract#1
Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation
循环肿瘤DNA(ctDNA)用于评估接受根治性化放疗的肛门癌患者的治疗反应
讲者：Janet Alvarez，MD
Abstract#285
The influence of procedural volume on the outcome of endoscopic submucosal dissection for gastric neoplasm: A nationwide population-based study
手术量对内镜粘膜下剥离术治疗胃癌结局的影响：一项基于人群的全国性研究
讲者：Jae Gyu Kim
Abstract#286
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Rationale 305:替雷利珠单抗联合化疗vs.安慰剂联合化疗作为晚期胃癌或胃食管结合部腺癌(GC/GEJC)一线治疗 (1L)的3期研究
讲者：Markus H. Moehler, MD, PhD
Abstract#287
Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2(HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC)
人表皮生长因子受体2低表达(HER2-L)vs.高表达(HER2-H)胃食管癌(GEC)的分子谱及肿瘤免疫微环境(TIME)的比较分析
讲者：Ali Algahtani, MD
口头摘要专场（Oral Abstract Session）
Abstract#4
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractormetastatic colorectal cancer: The phase 3 randomized SUNLIGHT study
曲氟尿苷替匹嘧啶联合贝伐珠单抗用于难治性转移性结直肠癌的三线治疗:3期SUNLIGHT随机研究
讲者: Josep Tabernero, MD, PhD
Abstract#5
Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage Ⅰ-Ⅲ colorectal cancer
术后循环游离DNA动力学及其对于手术切除后Ⅰ-Ⅲ期结直肠癌患者微小残留病灶（MRD）检出率的影响
讲者：Stacey A. Cohen MD
Abstract#6
Do nonoperative modality (NOM) treatments of rectal cancer compromise the chance of cure? Final surgical salvage results from OPERA phase 3randomised trial(NCTO2505750)
直肠癌的非手术治疗(NOM)会影响根治率吗? OPERA 3 期随机试验(NCT02505750)的最终挽救性手术结果
讲者：Arthur Sun Myint, FRCP FRCR
Abstract#7
Long-term results from NRG-GI002: A phase ll clinical trial platform usinototal neoadiuvant therapy (TNT) in locally advanced rectal cancer (LARC)
NRG-GI002 I期临床试验:全程新辅助治疗(TNT)用于局部晚期直肠癌(LARC)的长期结局
讲者：Thomas J. George, MD
Abstract#8
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma(ESCC): 29-month (mo) follow-up from CheckMate 648
纳武利尤单抗(NIVO)联合化疗(chemo)或伊匹木单抗（IPI）联合化疗作为晚期食管鳞状细胞癌(ESCC)的一线治疗: CheckMate-648的29个月随访数据
讲者：Ken Kato，MD, PhD
Abstract#291
Nivolumab(NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L)treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-vear follow-up from CheckMate 649
纳武利尤单抗(NIVO)联合化疗(chemo)vs.化疗作为晚期胃癌/胃食管交界癌/食管腺癌(GC/GEJC/EAC)的一线治疗: CheckMate-649的3年随访数据
讲者：Yelena Y. Janjigian，MD
Abstract#292
Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+)/ HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Zolbetuximab + mFOLFOX6作为claudin-18.2阳性(CLDN18.2+)/ HER2阴性局部晚期(LA)不可切除或转移性胃或胃食管交界处(mG/GEJ)腺癌患者(pts)的一线 (1L)治疗: 3期SPOTLIGHT研究的初步结果
讲者：Kohei Shitara, MD
Abstract#489
NRG/RTOG 1112:Randomized phase Ⅲstudy of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma(HCC)
NRG/RTOG 1112: 既往索拉非尼与立体定向放射治疗(SBRT)后接受索拉非尼治疗肝细胞癌(HCC)患者的随机Ⅲ期研究
讲者：Laura A. Dawson, MD, FASTRO, FRCPC
Abstract#491
Mbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer
lMbrave151: 一项阿替利珠单抗±贝伐珠单抗联合顺铂+吉西他滨治疗一线治疗的晚期胆道癌的 2 期、随机、双盲、安慰剂对照研究
讲者：Anthony B. El-Khoueiry, MD
Abstract#490
SWOG 1815: A phase Ⅲ randomized trial of gemcitabine. cisplatin. and nab paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
SWOG 1815:吉西他滨、顺铂和白蛋白结合型紫杉醇vs.吉西他滨和顺铂治疗新诊断的晚期胆道癌的Ⅲ期随机试验
讲者：Rachna T. Shroff, FASCO
Abstract#661
NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/ leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
NAPOLI-3：伊立替康脂质体+ 5-氟尿嘧啶/亚叶酸钙 + 奥沙利铂(NALIRIFOX) vs.白蛋白结合型紫杉醇 + 吉西他滨一线治疗转移性胰腺导管腺癌(mPDAC)患者的随机、开放标签 3 期研究
讲者：Zev A. Wainberg, MD
快速摘要专场（Rapid Abstract Session）
Abstract#10
Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy
直肠癌的器官保留和全程新辅助治疗:长程放化疗vs.短程放疗的探究
讲者：Paul Bernard Romesser，MD
Abstract#11
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase Ⅲ PARADIGM trial
RAS野生型转移性结直肠癌患者帕尼单抗的阴性过度选择: Ⅲ期 PARADIGM试验的生物标志物探索
讲者：Kohei Shitara, MD
Abstract#12
A double-blind, randomized, placebo-controlled, parallel study to investigate the auxiliary effects of fucoidan in patients with locally advanced rectal cancer who receive neoadiuvant concurrent chemoradiotherapy before surgery
双盲、随机、安慰剂对照、平行研究：探索褐藻糖胶（fucoidan）对术前接受新辅助同步放化疗的局部晚期直肠癌患者的辅助功效（auxiliary effects）
讲者：中国台湾，高雄医学大学附设中和纪念医院 Jaw-Yuan Wang ，MD，PhD
Abstract#132
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial
在无症状同步不可切除结直肠肝局限性转移患者中先行术前化疗而后行原发肿瘤切除：一项多中心随机对照试验
讲者：中国上海，复旦大学附属中山医院许剑民教授团队林奇医生，MD
Abstract#LBA8
Results from a phase Ⅰa/Ⅰb study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Botensilimab(BOT)(一种新型先天性/适应性免疫激活剂)联合balstilimab (BAL；抗PD-1抗体)治疗转移性重度预处理的微卫星稳定性结直肠癌(MSS CRC)的1a/1b期研究结果
讲者：Anthony B. El-Khoueiry, MD
Abstract#295
Neo-AEGIS(Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction lnternational Study):Final primary outcome analysis
Neo-AEGIS(食管腺癌新辅助试验和食管胃交界肿瘤的国际研究): 最终主要终点分析
讲者：Maeve Aine Lowery, MD
Abstract#305
Long-term outcomes after laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study (JCOG1401)
临床分期I期胃癌行腹腔镜辅助全胃切除术或近端胃切除术和淋巴结清扫术后的长期结果：日本临床肿瘤学组研究(JCOG1401)
讲者：Shinichi Sakuramoto
Abstract#358
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
INFINITY：替西木单抗和度伐利尤单抗作为微卫星不稳定性高(MSI-H)可切除胃癌或胃食管结合部腺癌(GAC/GEJAC)新辅助治疗的多中心、单臂、多队列Ⅱ期试验
讲者：Filippo Pietrantonio，MD
Abstract#381
Five-year follow-up results of a randomized phase Ⅲ trial comparing 4 and 8courses of S-1 adjuvant chemotherapy for pathological stage Ⅱ gastric cancer: JCOG1104(OPAS-1)
JCOG1104(OPAS-1)随机Ⅲ期试验：对比4个疗程vs.8个疗程的S-1辅助化疗治疗病理学分期Ⅱ期胃癌的五年随访结果
讲者：Souya Nunobe
Abstract#LBA294
INTEGRATE Ⅱa: A randomised, double-blind, phase Ⅲ study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG)
INTEGRATE Ⅱa：瑞戈非尼vs.安慰剂治疗难治性晚期胃食管癌(AGOC)的随机、双盲、Ⅲ期研究——一项由澳大利亚胃肠试验小组(AGITG)主导的研究
讲者：Nick Pavlakis, PhD，MBBS
Abstract#493
Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: A phase Ⅲ, multicenter, randomized, controlled trial
索拉非尼联合经动脉化疗栓塞术后辅助治疗肝细胞癌伴门静脉癌栓患者：一项 Ⅲ期、多中心、随机、对照试验
讲者：中国广东，中山大学附属第一医院匡铭教授
Abstract#494
Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-control
led phase 2 study
Nanvuranlat，一种L型氨基酸转运蛋白(LAT1)抑制剂，用于既往接受过治疗的晚期难治性胆道癌(BTC)患者：一项随机、双盲、安慰剂对照2期研究的主要终点结果
讲者：Junji Furuse, MD, PhD
Abstract#495
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population
替雷利珠单抗vs.索拉非尼一线治疗不可切除肝细胞癌: RATIONALE-301人群中健康相关生活质量影响分析
讲者：Richard S. Finn, MD
Abstract#662
Celiac plexus radiosurgery for pain management in advanced cancer: An international phase Ⅱ trial, health-related quality of life (HRQOL) outcome
腹腔神经丛放射外科治疗晚期癌症的疼痛管理：一项国际Ⅱ期试验，健康相关生活质量 (HRQOL) 结局
讲者：Yaacov Richard Lawrence MA, MBBSMRCP
Abstract#LBA492
Canadian Cancer Trials Group HE.1: A phase Ⅲ study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases
加拿大癌症试验组HE.1：姑息性放疗治疗症状性肝细胞癌和肝转移的Ⅲ期研究
讲者：Laura A. Dawson, MD, FASTRO, FRCPC
2023 ASCO GI即将来袭，【肿瘤资讯】将全程跟踪报道会议最新进展！
你心目中最值得期待的研究是哪一个？快在留言区告诉小编吧！
https://meetings.asco.org/meetings/2023-gastrointestinal-cancers-symposium/297/program-guide/scheduled-sessions
排版编辑：肿瘤资讯-Bree
苏公网安备 32059002004080号
